Get startedLog in
    Picture of Morphosys AG logo

    MOR — Morphosys AG News Story

    0.000.00%
    de flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMid CapMomentum Trap
    All News

    Brief: Morphosys Presents Preliminary Results From Phase 1/2 Study Of Tulmimetostat

    Picture of Morphosys AG logoMorphosys AG
    28/10/2022 06:55
    Oct 28 (Reuters) - MorphoSys AG  MORG.DE :
    * ON THURSDAY PRESENTED PRELIMINARY RESULTS FROM PHASE 1/2
STUDY
OF TULMIMETOSTAT (CPI-0209) SUPPORTING ITS POTENTIAL APPLICATION
IN A BROAD ARRAY OF ADVANCED TUMORS
    * THE STUDY SHOWED RESPONSES OR DISEASE STABILIZATION IN
FIVE
COHORTS WITH EVALUABLE PATIENTS

Source text for Eikon:  ID:nEQ2lRt2wa 
Further company coverage:  MORG.DE 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

    Recent news on Morphosys AG

    See all news